Entrar/Registro  
INICIO ENGLISH
 
Revista Mexicana de Neurociencia
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Mexicana de Neurociencia >Año 2018, No. 4


Ospina-García N, Cervantes-Arriaga A, Rodríguez-Violante M
Etiología, fenomenología, clasificación y tratamiento de la distonía
Rev Mex Neuroci 2018; 19 (4)

Idioma: Español
Referencias bibliográficas: 66
Paginas: 94-107
Archivo PDF: 469.09 Kb.


Texto completo




RESUMEN

En los últimos 30 años no sólo se han logrado avances importantes en los aspectos genéticos y fisiológicos de la distonía, sino en el abordaje diagnóstico, clasificación y en el tratamiento. Durante años se utilizaron exclusivamente medicamentos orales, con la introducción de la toxina botulínica y la estimulación cerebral profunda, sumado a los avances en el entendimiento de la enfermedad, se ha logrado impactar positivamente en la calidad de vida de quienes la padecen y sus familias. En este artículo realizaremos una actualización integral de la distonía desde su definición, fenomenología, clasificación, etiología y tratamiento.


Palabras clave: Distonía, genética, fenomenología, clasificación, toxina botulínica, estimulación cerebral profunda.


REFERENCIAS

  1. Ozelius LJ, Lubarr N, Bressman SB. Milestones in dystonia. Mov Disord. 2011;26 (6):1106-1126.

  2. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: A systematic review and meta-analysis. Mov Disord. 2012;27 (14):1,789-1,796.

  3. Alegría MA, Rodríguez VM, Zavala RA, López RM. Distonía cervical. Rev Mex Neurocienc. 2009;10 (2):90-102.

  4. Troiano R, Micheli FE, Alarco F. Movement disorders in Latin America. 2006; 12:125-138.

  5. Kuyper DJ, Parra V, Aerts S, Okun MS, Kluger BM. Nonmotor manifestations of dystonia: A systematic review. Mov Disord. 2011; 26 (7):1206-1217.

  6. H O. About a rare spasm disease of childhood and young age (Dysbasia lordotica progressiva, dystonia musculorum deformans). Neurol Cent. 1,911; 30:1,090-1,107.

  7. CD Marsden. Dystonia: The Spectrum of the Disease. Res Nerv Ment Dis. 1976; 55:351-367.

  8. Albanese A. How many dystonias? Clinical evidence. Front Neurol. 2017; 8:18.

  9. Fahn S ER. Definition of dystonia and classification of the dystonic states. Adv Neurol. 1976; 14:1-5.

  10. Albanese A, Lalli S. Update on dystonia. Curr Opin Neurol. 2012; 25 (4):483-490.

  11. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013; 28 (7):863-873.

  12. Jinnah HA, Delong MR, Hallett M. The dystonias: Past, present, and future. Mov Disord. 2013; 28 (7):849-850.

  13. Albanese A. Dystonia : clinical approach. 2007; 13:356-361.

  14. LeDoux MS. Dystonia: phenomenology. Parkinsonism Relat Disord. 2012; 18:S162-S164.

  15. Sitburana O, Chen Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Park Relat Disord. 2009;15 (10):758-761.

  16. Frucht SJ. The definition of dystonia: Current concepts and controversies. Mov Disord. 2013;28 (7):884-888.

  17. Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. Mov Disord. 2013;28 (7):958-967.

  18. Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nat Rev Neurosci. 2008;9 (3):222-234.

  19. Kaji R, Rothwell SJC, Katayama M, Ikeda T. Tonic Vibration Reflex and Muscle Afferent Block in Writer ’ s Cramp. 1995:155-162.

  20. Tinazzi M, Fiorio M, Fiaschi A, Rothwell JC, Bhatia KP. CME Sensory Functions in Dystonia : Insights from Behavioral Studies. 2009;24 (10):1427-1436.

  21. Bara-Jimenez W, Shelton P, Hallett M. Spatial discrimination is abnormal in focal hand dystonia. Neurology. 2000;55 (12):1,869- 1,873.

  22. Quartarone A, Bagnato S, Rizzo V, et al. Abnormal associative plasticity of the human motor cortex in writer’s cramp. Brain. 2003;126 (12):2,586-2,596.

  23. Quartarone A, Pisani A. Abnormal plasticity in dystonia: Disruption of synaptic homeostasis. Neurobiol Dis. 2011;42 (2):162-170.

  24. Ozelius LJ, Bressman SB. Genetic and clinical features of primary torsion dystonia. Neurobiol Dis. 2011;42 (2):127-135.

  25. Klein C. Genetics in dystonia. Park Relat Disord. 2014;20 (SUPPL.1):S137-S142.

  26. Xiao J, Uitti RJ, Zhao Y, et al. Mutations in CIZ1 Cause Adult Onset Primary Cervical Dystonia. 2012; 71 (4):458-469

  27. Bras J, Sheerin U, Charlesworth G, et al. Mutations in ANO3 Cause Dominant Craniocervical Dystonia : Ion Channel Implicated in Pathogenesis. 2012:1,041-1,050.

  28. Fuchs T, Saunders-pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet. 2013; 45 (1): 88–92.

  29. Lohmann K, Klein C. Update on the genetics of Dystonia. Curr Neurol Neurosci Rep. 2017;17 (3):26

  30. Camargos S, Cardoso F. Understanding dystonia: diagnostic issues and how to overcome them. Arq Neuropsiquiatr. 2016;74 (11):921-936.

  31. Fabbrini G, Berardelli I, Moretti G, et al. Psychiatric disorders in adult-onset focal dystonia: A case-control study. Mov Disord. 2010;25 (4):459-465.

  32. Lencer R, Steinlechner S, Stahlberg J, et al. Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatry. 2009;80 (10):1,176-1,179.

  33. Zoons E, Tijssen MAJ, Dreissen YEM, Speelman JD, Smit M, Booij J. The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. Eur J Nucl Med Mol Imaging. 2017;44 (8):1,375-1,382

  34. Berardelli I, Ferrazzano G, Pasquini M, Biondi M, Berardelli A, Fabbrini G. Clinical course of psychiatric disorders in patients with cervical dystonia. Psychiatry Res. 2015; 229 (1-2):583-585.

  35. Zurowski M, Mcdonald WM, Fox S, Marsh L. Psychiatric comorbidities in dystonia: Emerging concepts. Mov Disord. 2013;28 (7):914-920.

  36. Smit M, Kuiper A, Han V, et al. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: Results of a controlled study. Parkinsonism Relat Disord. 2016; 30:7-12.

  37. Lange F, Seer C, Dengler R, Dressler D, Kopp B. Cognitive Flexibility in Primary Dystonia. J Int Neuropsychol Soc. 2016;22 (6):662-670.

  38. Adam O, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13 (1):94-121.

  39. Burke RE FS. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol. 1983; 37:189-192.

  40. Hwang WJ, Calne DB, Tsui JKC, Fuente-ferna R De. The long-term response to levodopa in dopa-responsive dystonia. 2001; 8:18- 22.

  41. Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28 (7):1,001-1,012.

  42. Woolf SM, Baum CR. Baclofen. Uses and Complications. 2017;33 (4):271-275.

  43. Monbaliu E, Himmelmann K, Lin J, et al. Clinical presentation and management of dyskinetic cerebral palsy. 2017:741-749.

  44. Jabbari B. Reviews History of Botulinum Toxin Treatment in Movement Disorders. 1989:1-9.

  45. Müller J, Kemmler G, Wissel J, et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002;249 (7):842-846.

  46. Su MV, Direcci REZ, Investigaci DE, et al. Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients. Arq Neuropsiquiatr. 2016;10 (6):188-194.

  47. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Academy of Neurology. 2016;86 (19):1,818-1,826.

  48. Jankovic J. Botulinum Toxin : State of the Art Mechanism of Action and Pharmacology of BoNT. 2017;32 (8):1-8.

  49. Arango GJ, Fernández W. Indicaciones actuales para el uso de la toxina botulínica en neurología. Acta Neurologica Colombiana. 2004; 15:12-34

  50. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18 (1):5-18.

  51. Pirio Richardson S, Wegele AR, Skipper B, Deligtisch A, Jinnah HA. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017;88 (6):543-550.

  52. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol. 2007;6 (3):223-229.

  53. Krystkowiak P, Benabid A, Ph D, et al. Bilateral Deep-Brain Stimulation of the Globus Pallidus in Primary Generalized Dystonia. 2005:459-467.

  54. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystoniachoreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol. 2009;8 (8):709-717.

  55. Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol. 2012;11 (12):1029-1038.

  56. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology. 2009;73 (1):53-58.

  57. Marks WA, Honeycutt J, Acosta F, Reed M. Deep Brain Stimulation for Pediatric Movement Disorders. Semin Pediatr Neurol. 2009;16 (2):90-98.

  58. Cersosimo MG, Raina GB, Piedimonte F, Antico J, Graff P, Micheli FE. Pallidal surgery for the treatment of primary generalized dystonia: Long-term follow-up. Clin Neurol Neurosurg. 2008;110 (2):145-150.

  59. Meoni S, Fraix V, Castrioto A, et al. Pallidal deep brain stimulation for dystonia: a long term study. J Neurol Neurosurg Psychiatry. 2017:jnnp-2016-315504.

  60. Moro E, Gross RE, Krauss JK. What’s new in surgical treatment for dystonia? Mov Disord. 2013;28 (7):1,013-1,020.

  61. Aravamuthana Bhooma R, Waugha Jeff SSS. Deep brain stimulation for monogenic dystonia. Curr Opin Pediatr. 2017;29 (6):691- 696.

  62. Bronte-Stewart H, Taira T, Valldeoriola F, et al. Inclusion and exclusion criteria for DBS in dystonia. Mov Disord. 2011;26 (SUPPL.1):5-16.

  63. Thobois S, Taira T, Comella C, Moro E, Bressman S, Albanese A. Pre-operative evaluations for DBS in dystonia. Mov Disord. 2011;26 (SUPPL.1):17-26.

  64. Krause M, Fogel W, Tronnier V, Pohle S, Hörtnagel K, Thyen U VJ. Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration. Mov Disord. 2006;21 (12):2,255-2,257.

  65. Patel AJ, Sarwar AI, Jankovic J VA. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg. 2014; 82:241-244.

  66. Mills KA, Starr PA, Ostrem JL. Neuromodulation for Dystonia. Target and Patient Selection. Neurosurg Clin N Am. 2014;25 (1):59-75.



>Revistas >Revista Mexicana de Neurociencia >Año2018, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019